Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL

Clinical Trial Details

Overview

Research Study Summary

An 8-week, randomzied, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD).

Purpose

The purpose of this study is to find out if two different doses of agomelatine are safe and tolerable, and can help people who have major depressive disorder. The study doctor will also give agomelatine to some people in this study to find out if taking agomelatine is better than taking placebo. Placebo is a tablet that looks like an active drug but has no drug or other active ingredient

Please contact Alexian Brothers for more information on participation.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

8 Weeks

Facility Type

N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 176873

Date Last Changed: July 22, 2013


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.